<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02588378</url>
  </required_header>
  <id_info>
    <org_study_id>15-052</org_study_id>
    <nct_id>NCT02588378</nct_id>
  </id_info>
  <brief_title>The Role of Inflammation in AMD and Related Disorders</brief_title>
  <official_title>In Vivo Visualization of Active Macrophages and Retinal Pigment Epithelium (RPE) Damage in Age Related Macular Degeneration (AMD) &amp; Related Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, non-therapeutic study will compare the relative utility of multiple ocular
      imaging modalities in the detection of the cellular immune response in patients with AMD and
      related disorders.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visualization of RPE damage and presumptive immune cells</measure>
    <time_frame>8 months</time_frame>
    <description>Qualitative</description>
  </primary_outcome>
  <number_of_groups>9</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Early dry AMD (no GA)</arm_group_label>
    <description>multi-modal cSLO imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late dry AMD (with GA)</arm_group_label>
    <description>multi-modal cSLO imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reticular Pseudodrusen (RPD)</arm_group_label>
    <description>multi-modal cSLO imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polypoidal Choroidal Vasculopathy (PCV)</arm_group_label>
    <description>multi-modal cSLO imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retinal Angiomatous Proliferaion (RAP)</arm_group_label>
    <description>multi-modal cSLO imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Central Serous Retinopathy (CSR)</arm_group_label>
    <description>multi-modal cSLO imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RPE Detachment (RPED)</arm_group_label>
    <description>multi-modal cSLO imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New onset CNVM (wet AMD)</arm_group_label>
    <description>multi-modal cSLO imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy (non-AMD) controls</arm_group_label>
    <description>multi-modal cSLO imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>multi-modal cSLO imaging</intervention_name>
    <arm_group_label>Early dry AMD (no GA)</arm_group_label>
    <arm_group_label>Late dry AMD (with GA)</arm_group_label>
    <arm_group_label>Reticular Pseudodrusen (RPD)</arm_group_label>
    <arm_group_label>Polypoidal Choroidal Vasculopathy (PCV)</arm_group_label>
    <arm_group_label>Retinal Angiomatous Proliferaion (RAP)</arm_group_label>
    <arm_group_label>Central Serous Retinopathy (CSR)</arm_group_label>
    <arm_group_label>RPE Detachment (RPED)</arm_group_label>
    <arm_group_label>New onset CNVM (wet AMD)</arm_group_label>
    <arm_group_label>Healthy (non-AMD) controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male or female, 18 years of age or older, able to understand the study protocol and provide
        informed consent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria STUDY EYE

        Any tentative clinical diagnosis of the following:

          1. Early dry AMD (drusen) with clinical suspicion of CNV

          2. Late dry AMD (GA) with clinical suspicion of CNV

          3. Reticular Pseudodrusen with clinical suspicion of CNV

          4. Polypoidal choroidal vasculopathy

          5. Retinal Angiomatous Proliferation

          6. Central Serous Retinopathy

          7. RPE detachment

          8. Conversion to wet AMD (CNV)

          9. Decade matched controls

        Inclusion Criteria CONTROL EYE

          -  Subjects &gt; 18 years of age

          -  Best corrected visual acuity (BCVA) of 20/32 or better

        Exclusion Criteria STUDY/CONTROL EYE:

          -  Patients not able to provide consent for the study.

          -  Patients with a poor view of the fundus due to cataract or vitreous hemorrhage.

          -  Patients &lt; 18 years of age

          -  Patients with known allergy to angiographic dye

          -  Patients with any concurrent unrelated eye diagnosis that would interfere with image
             acquisition or interpretation (eg advanced diabetic retinopathy, vascular occlusion,
             uveitis, or others).

        Exclusion Criteria CONTROL EYE

          -  Suspect diagnosis of AMD, RPD, PCV, RAP, CSR or RPED

          -  Family history of AMD

          -  2 or more large drusen (&gt;125um) or 20 or more medium drusen (64-124um)

          -  Diabetes

          -  Patients using Plaquenil/Chloroquine/Hydroxychloroquine

          -  Diagnosis of inflammatory disease

          -  Patients with inherited eye disease

          -  Note: patients with a diagnosis of nevi are NOT excluded from this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shelley Boyd, MD</last_name>
    <phone>416-864-6060</phone>
    <phone_ext>2893</phone_ext>
    <email>BoydS@smh.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelley Boyd, MD</last_name>
      <phone>416-864-6060</phone>
      <phone_ext>2893</phone_ext>
      <email>BoydS@smh.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2015</study_first_submitted>
  <study_first_submitted_qc>October 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <last_update_submitted>August 9, 2016</last_update_submitted>
  <last_update_submitted_qc>August 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

